
Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc.(ALLO)内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签;可在本季度与近12个月之间切换;下方为季度图与交易明细。
SEC EDGAR · FMP · ALLO · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
16
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Allogene Therapeutics, Inc.内部人在过去近12个月主要在卖出股份,卖出行为通常由预设的Rule 10b5-1计划驱动,不一定代表对公司的负面看法。
▸ 数据来源:SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
ALLO 季度内部人买卖趋势
ALLO 内幕交易卖出 · ALLO 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源:SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · ALLO CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
ALLO 高管卖出股份 · ALLO 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Apr 21, 2026 | Yoshiyama Annie SVP, Finance | Sale | 9,586 | $22K | Form 4 |
| Mar 31, 2026 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Sale | 2,867 | $7K | Form 4 |
| Mar 16, 2026 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Sale | 4,835 | $12K | Form 4 |
| Mar 16, 2026 | Chang David D President and CEO · Director | Sale | 47,763 | $118K | Form 4 |
| Mar 2, 2026 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Sale | 7,132 | $19K | Form 4 |
| Feb 2, 2026 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Sale | 7,549 | $13K | Form 4 |
| Feb 2, 2026 | Chang David D President and CEO · Director | Sale | 95,269 | $171K | Form 4 |
| Feb 2, 2026 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Sale | 24,001 | $42K | Form 4 |
| Feb 2, 2026 | Douglas Earl Martin SVP, General Counsel | Sale | 22,900 | $40K | Form 4 |
| Feb 2, 2026 | Yoshiyama Annie SVP, Finance | Sale | 4,167 | $7K | Form 4 |
| Feb 2, 2026 | Roberts Zachary EVP of R&D | Sale | 35,700 | $63K | Form 4 |
| Jan 21, 2026 | Roberts Zachary EVP of R&D | Sale | 26,269 | $41K | Form 4 |
| Dec 18, 2025 | Kazam Joshua A Director | Option | 47,700 | — | Form 4 |
| Nov 17, 2025 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Sale | 786 | $959 | Form 4 |
| Oct 21, 2025 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Sale | 36,744 | $46K | Form 4 |
| Jun 10, 2025 | MESSEMER DEBORAH M. Director | Sale | 36,885 | $52K | Form 4 |
| Apr 21, 2025 | Yoshiyama Annie SVP, Finance | Sale | 9,601 | $14K | Form 4 |
| Mar 14, 2025 | Chang David D President and CEO · Director | Sale | 46,668 | $91K | Form 4 |
| Mar 14, 2025 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Sale | 5,488 | $11K | Form 4 |
| Mar 1, 2025 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Award | 31,755 | — | Form 4 |
| Feb 18, 2025 | MESSEMER DEBORAH M. Director | Sale | 13,313 | $32K | Form 4 |
| Feb 3, 2025 | Douglas Earl Martin SVP, General Counsel | Sale | 6,404 | $11K | Form 4 |
| Feb 3, 2025 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Sale | 4,361 | $8K | Form 4 |
| Feb 3, 2025 | MOORE TIMOTHY L. Chief Technical Officer | Sale | 14,746 | $25K | Form 4 |
| Feb 3, 2025 | Chang David D President and CEO · Director | Sale | 46,003 | $77K | Form 4 |
Beneski Benjamin Machinas
SVP, Chief Technical Officer
日期
Mar 31
股数
2,867
均价
$2.50
总金额
$7K
Beneski Benjamin Machinas
SVP, Chief Technical Officer
日期
Mar 16
股数
4,835
均价
$2.47
总金额
$12K
Beneski Benjamin Machinas
SVP, Chief Technical Officer
日期
Mar 2
股数
7,132
均价
$2.60
总金额
$19K
Beneski Benjamin Machinas
SVP, Chief Technical Officer
日期
Feb 2
股数
7,549
均价
$1.73
总金额
$13K
Beneski Benjamin Machinas
SVP, Chief Technical Officer
日期
Nov 17
股数
786
均价
$1.22
总金额
$959
Beneski Benjamin Machinas
SVP, Chief Technical Officer
日期
Mar 14
股数
5,488
均价
$1.98
总金额
$11K
Beneski Benjamin Machinas
SVP, Chief Technical Officer
日期
Mar 1
股数
31,755
均价
—
总金额
—
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源:SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 ALLO 内幕交易
ALLO 内幕交易
Allogene Therapeutics, Inc.(ALLO)内幕交易数据来源于公司内部人(包括Beneski Benjamin Machinas (SVP, Chief Technical Officer), Yoshiyama Annie (SVP, Finance), Chang David D (President and CEO · Director))提交的SEC Form 4申报文件。过去12个月内,5位内部人向SEC提交了交易申报。ALLO内部人近期主要在卖出,这可能反映预设的10b5-1计划执行,而非方向性判断。
如需查看Allogene Therapeutics, Inc.机构持仓比例和内部人持股百分比,请访问持仓(Ownership)标签页 → Ownership tab →
常见问题
ALLO 内幕交易 · 5个问题Allogene Therapeutics, Inc.(ALLO)的内部人包括高管和董事,如Beneski Benjamin Machinas (SVP, Chief Technical Officer), Yoshiyama Annie (SVP, Finance), Chang David D (President and CEO · Director)等。过去12个月内,5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源:FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026